Meeting
2020 ASCO Virtual Scientific Program
A phase II study evaluating atezolizumab (A), cobimetinib (C), and vemurafenib (V) in patients (pts) with BRAF-mutant melanoma and central nervous system (CNS) metastases (mets).
Authors
Paola Queirolo
Division of Medical Oncology for Melanoma, Sarcoma, and Rare Tumors, IEO, European Institute of Oncology IRCCS, Milan, Italy
Paola Queirolo , Luis De La Cruz Merino Sr., Ana Maria Abajo Guijarro , Hussein Abdul-Hassan Tawbi , Reinhard Dummer
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Melanoma/Skin Cancers
Track
Melanoma/Skin Cancers
Sub Track
Advanced/Metastatic Disease
Clinical Trial Registration Number
NCT03625141
Citation
J Clin Oncol 38: 2020 (suppl; abstr TPS10081)
DOI
10.1200/JCO.2020.38.15_suppl.TPS10081
Abstract #
TPS10081
Poster Bd #
430
Abstract Disclosures
Similar Posters
Poster
2021 ASCO Annual Meeting
Effects of baseline lactate dehydrogenase (LDH), interferon gamma (IFN-g) expression, and tumor mutational burden (TMB) on treatment response to first-line atezolizumab (A) + vemurafenib (V) and cobimetinib (C) in BRAFV600 mutation–positive advanced melanoma.
First Author: Caroline Robert
Poster
2023 ASCO Annual Meeting
A randomized phase 2 trial of encorafenib + binimetinib + nivolumab vs ipilimumab + nivolumab in BRAFV600-mutant melanoma brain metastases: SWOG S2000.
First Author: Zeynep Eroglu
Poster
2017 ASCO Annual Meeting
A randomized phase II study of vemurafenib plus cobimetinib continuous versus intermittent in previously untreated BRAF V600-mutation positive patients with unresectable locally advanced or metastatic melanoma.
First Author: Jose A. Lopez-Martin
Poster
2016 ASCO Annual Meeting
Phase 2 study of the safety and efficacy of pembrolizumab (pembro) in combination with dabrafenib (D) and trametinib (T) for advanced melanoma (KEYNOTE-022).
First Author: Georgina V. Long